Back to News
Market Impact: 0.4
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
Source: PR Newswire
Healthcare & BiotechM&A & RestructuringTechnology & Innovation
Novartis has entered an agreement for a worldwide license to Abogen Biosciences' ABO2203, an mRNA-encoded CD19xCD3 T-cell engager program. The deal also grants Novartis exclusive options to license additional potential programs using Abogen's proprietary RNA platform. The partnership validates Abogen's RNA technology and could expand Novartis' immuno-oncology pipeline, although financial terms were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
NVS0.65
More News
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Abogen signs $7.2 bln Novartis deal for mRNA autoimmune drug
- Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’
- David Ellison says combined Paramount and Warner Bros. Discovery will be named Skydance
- Paramount and Warner Bros Discovery to become Skydance
- FAA says Boeing 737 Max software glitch not a flight-safety issue
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?